Immunogen (IMGN) Tops Q4 EPS by 8c; Guides Higher
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
ImmunoGen Reports Recent Progress and 2019 Financial Results
February 14, 2020 6:30 AM ESTAccelerated Approval Pathway Defined for Mirvetuximab Soravtansine in Ovarian Cancer; Pivotal SORAYA Trial Expected to Enroll First Patient in Q1 2020
Phase 3 Confirmatory MIRASOL Trial for Mirvetuximab Enrolling Patients
Updated IMGN632 AML and BPDCN Monotherapy Data Presented at ASH
$97.6 Million Net Proceeds from Public Offering Extends Cash Runway to Second Half of 2022
Conference Call to be Held at 8:00 a.m. ET Today
WALTHAM, Mass.--(BUSINESS... More
